China available as an optional add-on for Prismaccess
Prioritis are pleased to announce that China is available as an optional add-on for Prismaccess. The data includes all reimbursed products...
Prioritis are pleased to announce that China is available as an optional add-on for Prismaccess. The data includes all reimbursed products...
A study conducted by Prioritis for G5 Santé and Leem has highlighted the difficult access of patients to recently approved...
The proposed ‘Innovative Medicines Fund’ extends the Cancer Drugs Fund (CDF) to include non-cancer diseases and is expected to be...
Chuikyo, a key reimbursement policy panel of the Japanese Central Social Insurance Medical Council has approved the cost-effectiveness assessment (CEA)...
In Spain, The Ministry of Health announced that in 2021 the Therapeutic Positioning Reports (IPT) will be conducted under a...
Tecartus (brexucabtagene autoleucel) is set to be reimbursed in England and Wales having received a recommendation for the Cancer Drugs...
As of 1st Jan 2021, Great Britain stopped following the EU centralised procedure for marketing authorisations. There are now many...
We hope this message finds you and your family in good health. The whole Prioritis team wishes you the very best...
The role of the EMA within the UK will continue until 31 December 2020. But the relationship remains uncertain from...
Prioritis has launched its PrismHEOR platforms reinforcing its unique offer of daily, intelligent and reliable published and upcoming data regarding...